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Abstract Galanin (GAL) is a widely distributed neuropeptide 
with diverse biological effects including modulation of hormone 
release, antinociception and modification of feeding behavior. Its 
effects are mediated through G-protein-coupled receptors 
(GPCR) for which only a single type has been cloned, GAL 
receptor 1 (GALR1). We describe the cloning of a second galanin 
receptor type, GALR2, from rat hypothalamus. The GALR2 
amino acid sequence is 38% identical to GALR1 and is 
pharmacologically similar to GALR1 when expressed in COS-
7 cells. GALR2 is encoded by a single gene containing at least 
one intron and expressed in a diverse range of tissues. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Galanin (GAL) is a widely distributed neuropeptide of 29 
or 30 amino acids with a broad spectrum of biological effects, 
which include altering hormone and neurotransmitter release, 
antinociception, smooth muscle contraction and relaxation 
and feeding behavior [1]. Interest in G A L has recently peaked 
because of its reported effects on feeding behavior. Hypo-
thalamic injection of G A L produces a dose-dependent in-
crease in feeding in satiated rats which can be blocked by 
peptide receptor antagonists and antisense oligonucleotides 
to G A L [2-5]. Thus, the development of G A L receptor antag-
onists may be useful in the treatment of obesity [3,6]. 
Originally isolated from porcine intestine in a search for C-
terminally amidated peptides [7], G A L has been found in 
humans and a wide range of species, with strict conservation 
of its primary sequence, particularly the first 15 residues [8]. 
As observed for most neuropeptides, G A L is synthesized as a 
part of a polyprotein precursor with canonical dibasic cleav-
age sites flanking mature G A L [9]. Studies of GAL gene ex-
pression localize its m R N A and protein to a variety of tissues 
[1,8-10], including the hypothalamus, hippocampus, locus co-
eruleus, anterior pituitary, spinal cord, pancreas and gastro-
intestinal tract. 
The biological effects of G A L are mediated by G-protein-
coupled receptors (GPCR) found at the cell surface of target 
cells which couple via pertussis toxin-sensitive G-proteins to 
downstream effector systems, including adenylate cyclase, 
phospholipase C and receptor-activated ion channels [1 ,11-
14]. Galanin receptor cDNAs [15-17] from human melanoma 
cells and rat brain (and insulinoma cells) have been reported. 
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G A L R 1 exhibits structural features consistent with G P C R s 
and is highly conserved between species. As predicted, 
G A L R 1 transiently expressed in C H O cells, couples in a neg-
ative fashion to adenylate cyclase [15,16]. G A L R 1 m R N A is 
prominently expressed in the hypothalamus, hippocampus, 
and spinal cord [15-18]. 
Distinct G A L receptor subtypes have been proposed [19,20] 
to account for the differential efficacy of G A L peptides to 
mimic GAL's actions and the variation in the ability of avail-
able chimeric peptides to serve as antagonists. We have used a 
low-stringency hybridization approach to identify and charac-
terize a new member of the G A L receptor family, which we 
refer to as G A L R 2 . 
2. Materials and methods 
2.1. Isolation and sequencing of galanin receptor cDNAs 
A cDNA library from rat hypothalamus was constructed in the 
plasmid-based mammalian vector pcDNA-3 (InVitrogen, San Diego, 
CA). Total RNA was isolated from freshly dissected rat hypothalami 
(flash-frozen in liquid nitrogen) using the RNAgents total RNA iso-
lation kit (Promega Biotech, Madison, WI) with a yield of approx-
imately 0.5 mg from 1 g (wet weight) of hypothalamic tissue. 
Poly(A)+ mRNA was selected using the Poly A tract mRNA Isola-
tion System III (Promega Biotech) with a yield of approximately 6 u.g 
from 0.5 mg total RNA. Three micrograms of poly(A)+ was then 
utilized as a template for cDNA synthesis using a kit (Choice Super-
script, Life Technologies, Gaithersberg, MD) with both random hex-
amer and oligo (dT)-Notl priming. The double-stranded cDNA was 
adapted for insertion into the BstXl site of pCDNA-3 using EcoRll 
BstXl adapters and transformed by electroporation into the Esche-
richia coli strain HB101. The resulting library contained approxi-
mately 750 000 primary transformants with 90% of the clones contain-
ing inserts (average size: 1-2 kb). The library ( = 700000 cfu) was 
plated onto LB plates containing ampicillin and chloramphenicol 
and probed with a ~280 bp PCR fragment (roughly encompassing 
the TM-2 to TM-4 region of GPCRs) which has been shown to 
hybridize to a broad set of GPCRs under reduced stringency condi-
tions. Hybridization was conducted at 32°C for 18 h in 5XSSPE 
buffer containing 50% formamide, 4XDenhardt's solution, 0.1%> 
SDS, 10% dextran sulfate, 30 ug/ml sheared salmon-sperm DNA 
with 2 X 106 cpm/ml of 32P-labeled probe. The probe was radiolabeled 
by random-priming with [oe-32P]dCTP to a specific activity of greater 
than 109 dpm/ug. The filters were then washed in 1 XSSC, 0.1% SDS 
at 55°C and exposed to film (Kodak X-omat) for 48 h. Two inde-
pendent positive clones were identified (designated 27A and 16.6) and 
subjected to further analysis. DNA was prepared from overnight cul-
tures using the Wizard DNA Purification System (Promega Corp., 
Madison, WI) and subjected to automated sequence analysis using 
the PRISM Dye Deoxy terminator cycle sequencing kit (Applied Bio-
systems, Foster City, CA) on an ABI 377 instrument. Initial sequenc-
ing primers were complementary to the T7 and SP6 promoter sites in 
pcDNA-3, additional primers were made complementary to the insert 
DNA. Database searches (Genbank, EMBL, Swiss-Prot, PIR, dEST, 
Prosite, dbGPCR), sequence alignments, and analysis of the GAL 
receptor nucleotide and protein sequences were carried out using the 
GCG Sequence Analysis Software Package (Madison, WI; PileUp, 
peptide structure and motif programs), FASTA and BLAST search 
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programs, and the PC/Gene software suite from Intelligenetics (San 
Francisco, CA; protein analysis programs). 
2.2. Expression of galanin receptor in COS-7 cells 
The EcoKl inserts from clones 27A and 16 were subcloned into the 
mammalian expression vector pCI.neo (Promega Biotech, Madison 
WI). Clones in the correct orientation were selected following a digest 
with BamHI. DNA was prepared using the Qiagen Maxi protocol 
(Qiagen, Chatsworth, CA) and transfected into COS-7 cells by elec-
troporation. Briefly, 0.85 ml of COS-7 cells in Ringer's buffer 
(1.2xl07/ml) and 20 (ig of DNA were mixed in a 0.4 mm electro-
poration cuvette (BioRad, Hercules, CA) and current (960 uF, 260 V) 
was applied using a BioRad Electroporator device. Cells were trans-
ferred to a T-180 flask (Corning) with fresh media and expression was 
allowed to proceed for 72 h. 
2.3. Membrane preparation and radioligand binding assay 
Membranes were prepared from transfected cells following disrup-
tion in enzyme-free dissociation solution (Specialty Media, Lavallette, 
NJ) in a Dounce homogenizer in ice-cold membrane buffer (10 mM 
Tris-HCl, pH 7.4, 10 mM PMSF, 10 uM phosphoramidon, and 40 ug/ 
ml bacitracin). After a low-speed (HOOXg, 10 min at 4°C) and a high-
speed centrifugation (38700Xg for 15 min at 4°C), membranes were 
suspended in buffer and the protein concentration determined (Bio-
Rad assay kit). Binding of 125I-labeled human galanin (sp. act.=2200 
Ci/mmol, DuPont NEN) was measured in membranes using a buffer 
of 25 mM Tris-HCl, pH 7.4, 0.5% BSA, 2 mM MgCl2, 40 ug/ml 
bacitracin, 4 ug/ml phosphoramidon, and 10 uM leupeptin in a total 
volume of 0.25 ml. 70 pM 125I-labeled human galanin was used. Re-
actions were initiated by the addition of membranes and the incuba-
tion was allowed to proceed at room temperature for 1 h. Non-specific 
binding was defined as the amount of membrane-bound radioactivity 
remaining in the presence of 1 uM cold GAL. In competition studies 
various concentrations of peptides (hGal, pGal, hGal(l-16), rGAL(2-
29), rGAL(3-29), hGal(l-19) or chimeric peptides (C7, M15, M40, 
M35) were included along with 125I-labeled hGal (70 pmol). Incuba-
tions were terminated by rapid filtration through GF/C filters which 
had been presoaked with 0.1% polyethylamine using a TOMTEC 
(Orange, CT) cell harvester. The results were analyzed using the Prism 
software package (GraphPad, San Diego, CA). 
2.4. Northern and Southern blot analysis 
Poly(A)+ mRNA was isolated from various rat tissues and cell lines 
as described above. Five micrograms of poly(A+) RNA from each 
tissue was denatured and run on a formaldehyde-MOPS gel and 
transferred directly after electrophoresis to a ZetaProbe GT mem-
brane (BioRad) by capillary transfer in 20XSSC. Northern blots 
were prehybridized at 42°C for 2 h in 5XSSPE, 2xDenhardt's sol-
ution, 100 ug/ml salmon sperm DNA, 0.1% SDS, and 50% forma-
mide. Hybridizations were carried out at 42°C for 20 h in the above 
solution containing 10% dextran sulfate and 1 X 106 cpm/ml of radio-
labeled probe, random-prime labeled with [a-32P]dCTP to a specific 
activity of greater than 109 dpm/ug. The probe used was a PCR frag-
ment of ~600 bp encompassing the majority of the ORF predicted 
by clone 27A (nt 1-618 of the ORF) beginning at the initiation codon 
and ending at transmembrane domain 5. The Northern blots were 
washed in 2XSSC, 0.1%> SDS at room temperature for 2x15 min, 
in 1XSSC, 0.1% SDS at 65°C for 2x15 min, and 0.1 xSSC, 0.1% 
SDS at 65°C for 1 h. RNA size standards were in vitro transcribed 
RNA markers (BRL). Nylon membranes containing .EcoRI-digested 
genomic DNA from several species (Clontech; 10 ug/lane) were hy-
bridized for 24 h at 30°C in 6XSSPE, lOxDenhardt's, 1% SDS, and 
50% formamide using a PCR-generated fragment of ~330 bp from 
the third intracellular loop to the C-terminal intracellular domain (nt 
667-999). Southern blots were washed twice with room temperature 
6XSSPE for 15 min each, twice with 55°C 6XSSPE for 15 min each, 
and twice with 55°C 4XSSPE for 30 min each. 
3. Results and discussion 
To isolate GAL receptor family members that may mediate 
the effects of GAL on the CNS, a rat hypothalamic cDNA 
library was screened under moderate hybridization conditions. 
The radiolabeled probe utilized has been shown to hybridize 
to several GPCRs under reduced stringency conditions. In 
addition to the GAL receptor described in this report, full-
length clones encoding neurotensin receptor type 2 and the 
growth hormone secretagogue receptor type la have also 
been isolated with this probe (unpublished observations). 
Out of ~ 750 000 independent clones screened, two clones, 
termed 27A and 16.6, were identified as positive through re-
peated rounds of screening. As outlined in Fig. 1 A, clone 27A 
contains the complete ORF for a 7-TM receptor divided into 
two exons by an unspliced intron of ~500 bp while clone 
16.6 contains a virtually identical ORF as a single contiguous 
reading frame. A perfectly conserved splice donor site (G/gt) 
is found at nucleotide 368 which coincides with the second 
residue of the GPCR signature aromatic triplet RY (Fig. 
1D,E). Exon 1 of clone 27A encodes the N-terminal extrac-
ellular domain through predicted TM-3, while exon 2 encodes 
the second predicted extracellular loop through the C-terminal 
intracellular domain. Both clones encode a polypeptide of 372 
amino acids (predicted molecular mass of 40.6 kDa) which 
differ by a single amino acid (residue 37 is L in clone 27A, 
F in clone 16.6) in the predicted TM-1, suggesting a possible 
polymorphism. Searches of nucleic acid and protein databases 
revealed that the nucleotide sequence is unique and most 
closely related to the rat GALR1 receptor with 55% nucleic 
acid and 38% protein sequence identity. 
An alignment of the protein sequences for rat GALR1 and 
GALR2 is given in Fig. 2. Several conserved features of 
GPCR were also identified in the rat GALR2: the signature 
aromatic triplet sequence (Glu-Arg-Tyr) adjacent to TM-3, 
Cys-98 and Cys-153 in the first two extracellular loops capable 
of disulfide bonding, putative amino-terminal N-glycosylation 
sites (Asn-Xaa-Ser/Thr), phosphorylation sites in the carbox-
yl-terminus and the third cytoplasmic loop, and conserved 
proline residues in TM-4, -5, -6 and -7. Compared to rat 
GALR1, rat GALR2 is overall 26 amino acids longer, the 
difference in length being centered at the amino terminus 
(GALR2 is eight amino acids shorter than GALR1), and 
the carboxyl terminal tail (GALR2 is longer by 34 amino 
acids). 
Membranes were prepared from COS-7 cells transiently 
transfected with GALR2, using either clone 27A or 16.6 
(both gave similar results) in order to assay 125I-labeled hu-
man GAL binding. As shown in Fig. 3A, saturable and spe-
cific high-affinity binding was observed to a single class of 
non-interacting sites with a AJ3=0.23 ±0.05 nM and Bmax of 
2.38 ±0.11 pmol/mg membrane protein. No binding was ob-
served in mock (vector only) transfected cells. To compare the 
pharmacological profiles of rat GALR1 and GALR2, compe-
tition studies were performed with GAL peptides (different 
Fig. 1. A: Schematic representation of rat GALR2 clones 27A and 16.6. Clone 27A is presumably a precursor mRNA containing an unspliced 
intron dividing the ORF into two exons. Clone 16.6 encodes a contiguous ORF for the complete GALR2 polypeptide. The putative splice junc-
tions in clone 27A (nt 368) are perfectly conserved in clone 16.6 which generates an AGG codon (Arg-123). B: Nucleotide and deduced amino 
acid sequence of rat GALR2 (clone 27A). Predicted transmembrane regions are underlined. Sites of potential N-linked glycoysylation are de-
noted by * whereas phosphorylation sites are given by +. 
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1 ATG AAT GGC TCC GGC AGC CAG GGC GCG GAG AAC ACG AGC CAG GAA GGC GGT AGC GGC GGC TGG CAG CCT GAG GCG 75 
1 M N G S G S Q G A E N T S Q E G G S G G W Q P E A 25 
76 GTC CTT GTA CCC CTA TTT TTC GCG CTC ATC TTC CTC GTG GGC ACC GTG GGC AAC GCG CTG GTG CTG GCG GTG CTG 150 
26 V L V P L F F A L I F L V G T ¥ G N A L ¥ L A V L 50 
1 5 1 CTG CGC GGC GGC CAG GCG GTC AGC ACC ACC AAC CTG TTC ATC CTC AAC CTG GGC GTG GCC GAC CTG TGT TTC ATC 225 
5 1 L R G G Q A V S T T N L F I L N L G V A D L C F I 75 
+ 
226 CTG TGC TGC GTG CCT TTC CAG GCC ACC ATC TAC ACC CTG GAC GAC TGG GTG TTC GGC TCG CTG CTC TGC AAG GCT 300 
76 I, C C V P F Q A T I Y T L D D W V F G S L L C K A 100 
301 GTT CAT TTC CTC ATC TTT CTC ACT ATG CAC GCC AGC AGC TTC ACG CTG GCC GCC GTC TCC CTG GAC AG 368 
101 V H F L I F L T M H A S S F T L A A ¥ S L D R 123 
369 gtaaaggacccagaaagaaacatccagtatgcccggagggatcttgactggaaaagactgaatcctggtctggtgacctt 
449 agttccctgccctttcacatcacttggacattcccacagaagagcggtgaagaggcggtggtccttattctcctctggtt 
529 tccactgagtgcaacatgtgcgtcctgagtacgctggagggactcacaaaatttcagctttctttaggagtttccttgct 
609 gtagtttgacccaagtcttctccaggtttctgtcagaacctcaggcatgagggatctgcctcccctggttgtcaccagag 
689 gataacaatcactgcccccagaaatccagacagattctacaacttttagtcttcggtgttttgggggtgccccttcacgt 
769 ggagtaggtcggtggccacattcccaggagtgacaatagcctagcagtgaatcctctcgcttagctgatgcccccccact 
849 gtccccacag 
+ 
859 G TAT CTG GCC ATC CGC TAC CCG CTG CAC TCC CGA GAG TTG CGC ACA CCT CGA AAC GCG CTG GCC GCC ATC GGG 931 
124 Y L A I R Y P L H S R E L R T P R N A L A A I G 147 
932 CTC ATC TGG GGG CTA GCA CTG CTC TTC TCC GGG CCC TAC CTG AGC TAC TAC CGT CAG TCG CAG CTG GCC AAC CTG 1006 
148 L I H £2 L A L L E 2 S E 1 L £ Y Y R Q S Q L A N L 172 
1007 ACA GTA TGC CAC CCA GCA TGG AGC GCA CCT CGA CGT CGA GCC ATG GAC CTC TGC ACC TTC GTC TTT AGC TAC CTG 1081 
173 T ¥ C H P A W S A P R R R A M D L C T F V F S Y L 197 
+ 
1082 CTG CCA GTG CTA GTC CTC AGT CTG ACC TAT GCG CGT ACC CTG CGC TAC CTC TGG CGC ACA GTC GAC CCG GTG ACT 1156 
198 r, P ¥ T, V T, S T, T Y A R T L R Y L W R T V D P ¥ T 222 
+ + 
1157 GCA GGC TCA GGT TCC CAG CGC GCC AAA CGC AAG GTG ACA CGG ATG ATC ATC ATC GTG GCG GTG CTT TTC TGC CTC 1231 
223 A G S G S Q R A K R K ¥ T R M I I I V A V L F C L 247 
1232 TGT TGG ATG CCC CAC CAC GCG CTT ATC CTC TGC GTG TGG TTT GGT CGC TTC CCG CTC ACG CGT GCC ACT TAC GCG 1306 
248 C W M P H H A T . T T . C V W F G R F P L T R A T Y A 272 
1307 TTG CGC ATC CTT TCA CAC CTA GTT TCC TAT GCC AAC TCC TGT GTC AAC CCC ATC GTT TAC GCT CTG GTC TCC AAG 1381 
273 L R I L S H L ¥ S Y A N S C ¥ H P I V Y A L V S K 297 
+ 
1382 CAT TTC CGT AAA GGT TTC CGC AAA ATC TGC GCG GGC CTG CTG CGC CCT GCC CCG AGG CGA GCT TCG GGC CGA GTG 1456 
298 H F R K G F R K I C A G L L R P A P R R A S G R V 322 
* + 
1457 AGC ATC CTG GCG CCT GGG AAC CAT AGT GGC AGC ATG CTG GAA CAG GAA TCC ACA GAC CTG ACA CAG GTG AGC GAG 1531 
323 S I L A P G N H S G S M L E Q E S T D L T Q V S E 347 
* + 
1532 GCA GCC GGG CCC CTT GTC CCA CCA CCC GCA CTT CCC AAC TGC ACA GCC TCG AGT AGA ACC CTG GAT CCG GCT TGT 1606 
348 A A G P b V P P P A L P N C T A S S R T L D P A C 372 
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Fig. 2. Alignment of amino acid sequences for rat GALRl and GALR2 (clone 27A). The PileUp program (GCG Program Suite, Madison, 
WI) was utilized to compare sequences. 
species or truncated peptides) and the chimeric peptides. As 
given in Table 1, the rank order of potency for the tested 
chimeric peptides is similar between the two receptor types: 
M35 > M40 > C7, galantide. However, GALR2 shows a 10-
fold lower affinity for 125I-labeled human GAL, whether as-
saying rat, human or porcine GAL (rat GALRl has an affin-
ity for human GAL of 0.02 nM; unpublished observations). 
Both GALRl and GALR2 share a requirement for the amino 
terminal residues of GAL for high-affinity binding as evi-
denced by the lack of binding to rGAL(3-29). Thus both of 
these receptors are distinct from the receptors proposed to 
Table 1 
Pharmacology of rat GALRl and GALR2 
Porcine GAL 
Human GAL 
Rat GAL(2-29) 
Rat GAL(3-29) 
Porcine GAL(1-16) 
Galantide (Ml5) 
C7 
M40 
M35 
IC50 (nM) 
Rat GALRl 
0.06 
0.07 ±0.01 
7.2 
>1000 
0.27 ±0.18 
l . O t l . l 
4.9 ±3 
0.9 ±0.6 
0.01 
Rat GALR2 (clone 27A) 
0.46 
1.3±0.5 
2.9± 1.3 
>1000 
3.0 
28 ±3.5 
23 ±13 
1.9±0.14 
0.43 ±0.18 
IC50 values were calculated from displacement curves of 5I-labeled 
human GAL binding using non-linear regression analysis (Prism V2.0, 
GraphPad Software, San Diego, CA). 
exist in the pituitary and in the gut which are insensitive to 
delections of the first two amino acids of GAL. There is a 
subtle difference in the affinity of GALR2 for porcine GAL, 
while GALRl does not distinguish between the human, rat 
and porcine GALs. This suggests that the GALR2 receptor 
may respond in a different way to changes in the carboxy 
terminal region of native GAL. Differences in IC50 values 
were noted for most peptides against GALRl and GALR2 
such that between 5- to 30-fold higher concentrations of test 
peptide was needed for 50% inhibition against GALR2. One 
explanation for the overall lower affinity of 125I-labeled hu-
man GAL to rat GALR2 may be species differences: rat 
GALR2 shows a much higher affinity for porcine GAL versus 
human GAL. 
Transcripts encoding GALR2 were readily detected in sev-
eral rat tissues, with expression in RINm5F cells and uterus 
being most prominent (Fig. 4A). Expression of GALR2 in 
RINm5F cells suggests that the previously studied pharmaco-
logical properties of these cells was complicated by a mixed 
receptor population composed of at least two receptor types. 
Genomic Southern analysis suggests that GALR2 is encoded 
by a single conserved gene, as a simple hybridization pattern, 
indicative of a single gene only was noted in several species 
(see legend to Fig. 4 for details). 
In summary, we have isolated a full-length cDNA encoding 
a second member of the GAL receptor family. Despite the 
amino acid differences between the GALRl and GALR2 re-
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Fig. 3. Pharmacological characterization of rat GALR2. Clone 27A was sub-cloned into a mammalian expression vector, transfected into COS-
7 cells, and 72 h following tranfection, cell membranes were assayed for human 125I-labeled GAL binding. For saturation isotherm and Scatch-
ard analysis, 3 |ig of membrane protein was used for each assay point (triplicate measurements). 
Fig. 4. Northern and Southern blot analysis of rat GALR2 expression. A: An RNA blot was prepared using poly(A+) mRNA (1 (xg/lane) 
from: lane 1, heart; lane 2, kidney; lane 3, liver; lane 4, lung; lane 5, skeletal muscle; lane 6, prostate; lane 7, testes; lane 8, vas deferens; 
lane 9, uterus; lane 10, ovary; lane 11, stomach; lane 12, large intestine; lane 13, pancreas; lane 14, RIN m5F cells. Upper panel: the radiola-
beled probe utilized encompasses most of the GALR2 ORF from the initiation codon through TM-5. Following high-stringency post-hybridiza-
tional washing, the blot was exposed to X-ray film for 3 days at —70°C. RNA size marker (Life Technologies) are 9.5, 7.5, 4.4, 2.4, and 1.35 
kb. Lower panel: the same blot hybridized with a radiolabeled actin probe to normalize mRNA loaded. B: A commercial genomic Southern 
blot (EcoRI-digested DNA, 10 jig/lane) was hybridized with a 3'-fragment of the rat GALR2 ORF (third intracellular loop to C-terminal intra-
cellular domain). Post-hybridizational washing stringencies were at 55°C 4XSSPE after which the filters were dried and exposed to X-ray film 
for 5 days at —70°C. Lane 1, lambda Hindlll markers (23.1, 9.4, 6.6, 4.4, 2.3, 2.1 kb); lane 2, human; lane 3, monkey; lane 4, rat; lane 5, 
mouse; lane 6, dog; lane 7, cow; lane 8, rabbit; lane 9, chicken; lane 10, yeast. 
ceptors their pharmacological profile is remarkably similar. 
Therefore in order to distinguish what role each receptor plays 
in mediating the biological effects of G A L , one must await the 
development of G A L receptor subtype-specific antagonists or 
targeted disruption of each receptor gene. 
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